Whole-genome mapping of APOBEC mutagenesis in metastatic 1

urothelial carcinoma identifies driver hotspot mutations and a 2

3

novel mutational signature

- J. Alberto Nakauma-González^{1,2,3,*}, Maud Rijnders³, Minouk T. W. Noordsij¹, John W. M. Martens³, 4
- Astrid A.M. van der Veldt^{3,4}, Martiin P. J. Lolkema^{3,6}, Joost L. Boormans², Harmen J. G. van de 5
- Werken^{1,2,5,7,*} 6
- 7 ¹Cancer Computational Biology Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam,
- Rotterdam 3015 GD, the Netherlands
- 8 9 ²Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam 3015
- 10 GD, the Netherlands
- 11 ³Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam,
- 12 Rotterdam 3015 GD, the Netherlands
- 13 14 ⁴Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, the Netherlands
- 15 ⁵Department of Immunology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam 16 17 3015 GD, the Netherlands
- ⁶Currently employed by Amgen Europe BV, Breda 4817 ZK, the Netherlands
- 18 ⁷Lead contact

*Correspondence: j.nakaumagonzalez@erasmusmc.nl (JAN), h.vandewerken@erasmusmc.nl (HJGvdW), Cancer

19 20 21 22 Computational Biology Center & Department of Immunology, Department of Urology, Erasmus MC Cancer

Institute, University Medical Center, Rotterdam, the Netherlands. PO Box 2040, 3000 CA, NA-1218.

23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 SUMMARY

25 APOBEC enzymes mutate specific DNA sequences and hairpin-loop structures, challenging the 26 distinction between passenger and driver hotspot mutations. Here, we characterized 115 whole-27 genomes of metastatic urothelial carcinoma (mUC) to identify APOBEC mutagenic hotspot drivers. 28 APOBEC-associated mutations were detected in 92% of mUC and were equally distributed across the 29 genome, while APOBEC hotpot mutations (ApoHM) were enriched in open chromatin. Hairpin-loops 30 were frequent targets of didymi (twins in Greek), two hotpot mutations characterized by the APOBEC 31 mutational signature SBS2, in conjunction with an uncharacterized mutational context (Ap[C>T]), which 32 was associated with DNA mismatch. Next, we developed a statistical framework that identified 0.40% 33 of ApoHM as drivers of mUC, which affected known driver genes and non-coding regions near exons of 34 potential novel driver genes. Our results and statistical framework were validated in independent cohorts 35 of 23 non-metastatic UC and 3744 samples of 17 metastatic cancers, identifying cancer-type-specific 36 drivers. Our study highlights the role of APOBEC in cancer development and may contribute to 37 developing novel targeted therapy options for APOBEC-driven mUC.

38

39 KEYWORDS

40 APOBEC; breast cancer; didymi; driver mutations; hairpin-loops; hotspot mutations; pan-cancer;
41 mutational signature; twin mutations; urothelial carcinoma

42

44 INTRODUCTION

45 Cancer genomes accumulate somatic mutations via different mutagenic processes and one of the most 46 common is attributed to the apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) 47 family¹. APOBEC has a specific mutational signature, which is characterized by C>T/G mutations in the 48 TpC context and is captured in the SBS2 and SBS13 signatures, as defined by the Catalogue Of Somatic 49 *Mutations In Cancer* (COSMIC)². In some tumor types with high APOBEC activity, the contribution to the tumor mutational burden is substantial, which increases the neoantigen load favoring response to 50 immune checkpoint inhibitors^{3,4}. However, APOBEC is also responsible for the emergence of driver 51 52 mutations that contribute to cancer development as shown in mouse models⁵. Discriminating driver 53 events from passenger events is essential to reconstruct the evolutionary history of cancers and identify 54 effective novel drug targets in APOBEC-driven tumors.

55 The mutational process of APOBEC has been extensively studied, revealing its preference for single-56 stranded DNA structures that form hairpin-loops⁶. This characteristic of APOBEC could result in identical 57 somatic mutations in tumors from multiple patients, so-called hotspot mutations or hotspots. Due to their 58 high prevalence, these hotspots can erroneously be assigned as driver mutations, especially in the non-59 coding area of the genome. However, the vast majority of mutations are passengers and do not 60 contribute to cancer development, and the same principle may also apply to hotspot mutations⁷. Although bioinformatic strategies to identify driver hotspot mutations have been developed^{8,9}, the unique 61 62 characteristics of the APOBEC mutagenic process require specific considerations to account for all co-63 variables accurately.

64 APOBEC-derived mutations are a dominant contributor to the mutational landscape in urothelial 65 carcinoma (UC). Therefore, we analyzed whole-genome DNA-sequencing data of 115 metastatic UC 66 (mUC) and matched blood samples¹⁰ to identify driver hotspot mutations in the context of APOBEC 67 mutagenesis. The comprehensive characterization of APOBEC-enriched tumors identified a novel 68 mutational signature associated with DNA mismatch repair as well as genomic co-variates associated 69 with APOBEC-derived hotspot mutations (ApoHM), which we used to develop a statistical framework 70 and identify driver ApoHM. Furthermore, our findings were validated in whole-genomes of an 71 independent cohort of 23 non-metastatic UC, and the analysis was extended to include 442 metastatic 72 breast cancer (mBC) and 3302 samples 16 other metastatic cancer types.

73 RESULTS

74 APOBEC mutagenesis dominates the mutational landscape of urothelial carcinoma

75 The analysis of whole-genome sequencing (WGS) data of mUC and matched blood samples revealed 76 a median of 20,667 (Q1=14,304, Q3=31,411) single nucleotide variants (SNVs) per tumor. mUC with a 77 significant enrichment (E) for C>T mutations in TCW (W = A or T) context were considered APOBEC 78 positive (92%). These tumors were further stratified according to APOBEC enrichment as APOBEC-79 high (41%; E>3), APOBEC-medium (33%; 2<E<3), and APOBEC-low (18%; E>1) (Figure 1A). The 80 median contribution of APOBEC COSMIC signatures (SBS2+SBS13) in APOBEC-high, -medium and -81 low tumors was 61%, 37% and 15%, respectively. For the remaining 8% of tumors lacking APOBEC mutations, the median APOBEC signature was <2%, potentially reflecting the noise of the mutational 82 signature calling. We associated the APOBEC stratification with multiple factors to better assess the 83 84 different APOBEC subtypes. Tumor purity, for instance, declined with increasing APOBEC mutagenesis 85 (Figure S1). Moreover, age was associated with the enrichment of APOBEC mutations (Figure S1). 86 The median clonal fraction of SNVs was lower in tumors with APOBEC mutations than in non-APOBEC 87 tumors, suggesting higher tumor heterogeneity in APOBEC-enriched tumors (Figure S1). Localized 88 hypermutation events (kataegis) strongly correlated with APOBEC enrichment (spearman r=0.80, 89 p<0.001). Homologous recombination (HR) deficiency (n=3) was only present in APOBEC-low tumors 90 (Fisher's exact p=0.005), while none of the patients with microsatellite instability (MSI; n=4) had 91 evidence of APOBEC mutagenesis (Fisher's exact p<0.001). Structural variants were more frequent in 92 APOBEC tumors than in non-APOBEC tumors (Figure S1). Additionally, APOBEC tumors had a higher 93 ploidy (median ploidy = 3) and a higher number of genes affected by copy number alterations (CNA) 94 than non-APOBEC tumors (Figure S1), suggesting genomic instability in APOBEC-driven mUC tumors. 95 APOBEC mutagenesis was not associated with sex, the primary origin of mUC (upper tract versus 96 bladder) or chromothripsis.





98 Figure 1. Genomic landscape and APOBEC activity of metastatic urothelial carcinoma (n=115)

stratified by APOBEC-enrichment 99

100	(A) Whole-genome sequencing data of metastatic urothelial carcinoma (mUC) were classified
101	according to the enrichment of APOBEC-associated mutations as having high, medium, low or
102	no APOBEC enrichment. The genomic features are displayed from top to bottom as follows:
103	APOBEC mutagenesis; genomic subtype (GenS1-5) as previously described ¹⁰ ; genome-wide
104	tumor mutational burden (TMB); mutational signatures grouped by etiology, while both
105	APOBEC signatures are shown separately; absolute frequency of structural variants (SV);
106	relative frequency of SV categories; clonal fraction; ploidy; tumor purity; microsatellite
107	instability (MSI) status; homologous recombination (HR) deficiency status; samples with at
108	least one chromothripsis event; frequency of kataegis events; female patients and; primary
109	origin of mUC (upper tract versus bladder).
110	(B) Expression of APOBEC and AICDA genes in 90 samples with available RNA-sequencing
111	data.

(C) Pearson correlation of RNA expression of APOBEC3A and APOBEC3B. 112

113 (D) Fold enrichment of C>T and C>G alterations in YTCA (related to APOBEC3A) and RTCA

114 (related to APOBEC3B) context.

- 115 (E) APOBEC score (normalized expression of *APOBEC3A+APOBEC3B*).
- (F) Percentage of mRNA C>U mutations in DDOST at position chr1:20981977. In (B), (E) and (F),
- 117 the Wilcoxon rank-sum test was applied to compare APOBEC tumors vs. non-APOBEC
- 118 tumors. P-values were Benjamini-Hochberg corrected in (B).
- 119 See also Figures S1-S5.

120

121 APOBEC mutagenesis is an ongoing process in metastatic lesions of urothelial carcinoma

122 Next, we analyzed RNA-sequencing data of 90 matched samples of mUC. Pathway activity based on 123 downstream gene expression, such as cell cycle or p53 was similar between the APOBEC groups 124 (Figure S2). Similarly, analysis of APOBEC expression of all genes of the APOBEC family (APOBEC1 125 was not expressed) revealed no significant differences between APOBEC and non-APOBEC tumors (Figure 1B). We detected a weak positive correlation between the expression of APOBEC3A and 126 127 APOBEC3B (Figure 1C). To further investigate the mutagenic activity of both enzymes, the fold 128 enrichment of C>T and C>G mutations, at DNA level, in the tetra-base YTCA (related to APOBEC3A; Y are pyrimidine bases) and RTCA (related to APOBEC3B; R are purine bases) context was calculated¹¹ 129 130 (Figure 1D). In both cases, YTCA and RTCA mutations did not correlate with expression of APOBEC3A 131 or APOBEC3B (Figure S3). The lack of correlation might be linked to the heterogeneous expression of APOBEC enzymes that oscillate throughout the cell cycle^{12,13}. Furthermore, we detected that both, 132 133 APOBEC3A and APOBEC3B, contributed to APOBEC-associated mutations (fold enrichment is above 134 1.0). Nevertheless, APOBEC3A appeared to be the main contributor as suggested in primary 135 cancers^{11,14}. Considering the mRNA expression of both APOBEC3A and APOBEC3B enzymes, we 136 calculated the APOBEC expression score (sum of the normalized expressions of APOBEC3A and APOBEC3B). It appeared that the level of APOBEC enrichment correlated with the APOBEC expression 137 138 score (Figure 1E). This analysis confirmed the link between APOBEC RNA expression at the time of biopsy and the historical accumulation of APOBEC-associated mutations in mUC that others have 139 140 reported in primary urothelial carcinoma^{15,16}.

Recently, it was proposed that edited *DDOST* mRNA can be used to measure ongoing APOBEC mutagenesis¹⁷. We found that the frequency of C>U alterations in the *DDOST* mRNA at position

143 chr1:20981977 was enriched in tumors with APOBEC mutagenesis, with up to 15% of mRNA reads edited in one single sample (Figure 1F). Additionally, we analyzed ongoing APOBEC mutagenesis in 144 145 mUC, by WGS of eight tumors from patients who had undergone serial biopsies of metastatic lesions 146 (Figure S4). We observed that the APOBEC mutational signature was present in private mutations of 147 the second biopsy of these patients, suggesting that APOBEC mutagenesis could be active in the period 148 between the first and second biopsy (Figure S4A). A lower cancer cell fraction (normalized allele 149 frequency by copy number and purity, see Methods) in private SNVs of the second biopsy compared to 150 shared (trunk) mutations confirms that these mutations were acquired more recently as they are only 151 present in a subpopulation of cancer cells (Figure S4B). This result, together with the APOBEC signature detected in the subclonal mutations (Figure S5), suggests that the presence of subclonal 152 153 populations due to APOBEC mutagenesis may contribute to the ongoing evolution of UC in the 154 metastatic setting.

155

156 APOBEC-associated hotspot mutations are enriched in highly accessible genomic regions

157 The high resolution achieved by WGS, allowed us to investigate the enrichment of APOBEC and non-158 APOBEC mutations (non-TpC context) in specific genomic regions. We found that the number of non-159 APOBEC-associated SNVs, for instance, varied across the genome (Figure 2A). When this distribution 160 overlapped with DNA accessibility and overall gene expression level, the frequency of non-APOBEC 161 mutations decreased in open chromatin (highly accessible regions) and highly transcribed regions 162 (Figure 2B). In contrast, the frequency of APOBEC-associated mutations was nearly constant across 163 the genome. When restricting the analysis to APOBEC tetra-base mutations, we found that the 164 difference in the distribution of Y/RTCA mutations across genomic regions decreases with the level of 165 APOBEC enrichment (Figure 2C). Interestingly, in APOBEC-high tumors, YTCA mutations were evenly 166 distributed. In contrast, RTCA mutations were enriched in low DNA accessible and low transcribed 167 regions, although this enrichment was considerably less compared to tumors with lower levels of 168 APOBEC mutations.



Figure 2. Distribution of APOBEC-associated mutations across genomic regions of metastatic 170 171 urothelial carcinoma

172 (A) Whole-genome sequencing data (n = 115) were analyzed to estimate the mean number of 173 single nucleotide variants (SNVs) in windows of one mega base pair (Mbp) across the entire 174 genome. The circos plot shows from outer to inner circles: the genomics ideogram from chromosome 1 to X where the centrosomes are indicated in red; the mutational load of 175 176 APOBEC and non-APOBEC associated mutations (mutations in TpC or non-TpC context, 177 respectively); The density of kataegis events; Average RNA counts (expression) from tumors with available RNA-sequencing data (n = 90); DNA accessibility estimation from different 178

179	ChIPseq experiments of multiple histone marks from normal urothelial samples derived from
180	ENCODE ⁴⁵ . Peaks represent highly accessible DNA.
181	3) Linear regression of the mutational load for APOBEC- and non-APOBEC-associated
182	mutations as well as the density of kataegis events across the genome with DNA accessibility
183	and expression data.
184	C) Relative distribution of APOBEC YTCA and RTCA mutations across DNA-accessible and RNA
185	expression regions. Samples were stratified according to the level of APOBEC mutagenesis.
186	The Wilcoxon signed-rank test was applied and p-values were Benjamini-Hochberg corrected.
187) Frequency of hotspot mutations grouped according to APOBEC and non-APOBEC-associated
188	mutations, and DNA accessibility or RNA expression level.

189

190 Because of the high correlation between kataegis and APOBEC enrichment, we analyzed the 191 distribution of kataegis loci across the genome. Contrary to the overall distribution of SNVs, our data 192 suggest that kataegis events are more likely to occur in regions with high DNA accessibility and high 193 transcriptional activity (Figure 2B). Moreover, we also evaluated the genome-wide distribution of all 194 hotspot mutations (two or more mutations in a specific genomic position), representing 0.35% of all 195 mutated genomic positions. We found that the frequency of highly recurrent (n≥4) ApoHM were enriched 196 in high DNA accessibility and high transcriptional active regions (Figure 2D). Thus, while general 197 APOBEC mutagenesis seemed to occur uniformly across the genome, kataegis and ApoHM seemed to 198 occur more frequently in open chromatin and highly transcribed loci.

199

200 Recurrent hotspot mutations correlate with APOBEC mutagenesis

201 Next, we investigated the genomic consequence of hotspot mutations and found that the most frequent 202 hotspot mutations in mUC occurred in non-coding regions of the genome (Figure 3A). Hotspot 203 mutations in the TERT promoter were present in 62% of tumors. In line with previous reports^{18,19}, TERT 204 expression did not differ between tumors with hotspot mutations and those being wildtype (Figure S6A). 205 However, differential gene expression analysis showed that tumors with hotspot mutations in the TERT 206 promoter had high expression of genes related to the biological oxidation pathway (Figure S6B, Table 207 **S1**). Besides TERT, other frequent hotspot mutations were identified in the non-coding regions near 208 ADGRG6 (40%), PLEKHS1 (33%), LEPROTL1 (20%), and TBC1D12 (15%). Similarly, these hotspot

209 mutations did not affect the expression of these genes but were associated with transcriptomic effects 210 in several genes (Figure S6) and biological pathways (Table S1). These hotspot mutations strongly 211 correlated with enrichment for APOBEC-associated mutations, suggesting their origin in APOBEC

212 mutagenesis (Figure 3B).



213

214 Figure 3. Recurrent hotspot mutations of metastatic urothelial carcinoma correlate with APOBEC

- 215 mutagenesis
- 216 (A) Overview of recurrent hotspot mutations present in at least five samples, including all
- 217 substitutions occurring in the same genomic position. Hotspot mutations occurring in the TpC 218 context are highlighted in red.
- 219 (B) The association of hotspot mutations and APOBEC fold enrichment (continuous values) was
- 220 interrogated with a logistic regression analysis applying the Wald test. P-values were

221	corrected using the Benjamini-Hochberg method and ordered accordingly. Bars above the
222	dashed line ($-\log_{10}(0.05)$) are statistically significant and are indicated in red.

223 See also Figure S6 and Table S1.

224

All frequent hotspot mutations in the coding region have been previously described and affected known driver genes: *FGFR3* S249C/R248C (8%, 4%), *PIK3CA* E54K (7%), *RXRA* S427F/Y (7%) and *TP53* E285K/* (6%). Comparing the expression of these known driver genes affected by hotspot mutations vs. the wildtype, only *FGFR3* hotspot mutations significantly affected the expression of this gene (**Figure S6A**).

230

231 Hairpin-loops are targets of twin hotspot mutations called Didymi

232 We noticed that the hotpot mutations near ADGRG6, PLEKHS1, LEPROTL1 and TBC1D12 are located 233 within DNA hairpin-loop structures. It is known that DNA hairpin-loops are targets of APOBEC3A (Figure 234 **4A**)^{20,21}, therefore, we predicted DNA hairpin-loops for all mutated genomic positions (see Methods). 235 The predicted hairpin-loops near ADGRG6, PLEKHS1, LEPROTL1 and TBC1D12 are each affected by two hotspot mutations, which are referred to as twin mutations²¹. Moreover, we noticed that the twin 236 237 mutations were not mutually exclusive, which differs from the hotspot mutations in the TERT promoter 238 (mutual exclusivity test, p < 0.001). Only the twin hotspot mutations in TBC1D12 co-occurred more 239 frequently than expected among APOBEC-high tumors (p = 0.02). Further analysis of co-occurred twin 240 hotspot mutations revealed that very few had identical variant allele frequencies, suggesting that most 241 twin mutations in the same tumor occurred in independent events as they were also found on different 242 alleles (Figure S7).



244 Figure 4. Genomic characteristics of twin hotspot mutations in metastatic urothelial carcinoma

(A) Hairpin-loop structures affected by frequent hotspot mutations in ADGRG6, TBC1D12, 245 PLEKHS1 and LEPROTL1. The positions of hotspot mutations are marked in red for TpC 246 247 context and blue otherwise.

248 (B) Distribution of twin mutations according to the distance between twin mutations and loop size.

- 249 (C) Mutational signatures (COSMIC v3.3) of twin mutations according to their frequency. The 250 stability of the signature call was tested by applying 1,000 bootstrap iterations. Only SBS2 was 251 very stable in highly frequent ($n \ge 5$) twin mutations.
- 252 (D) Frequency distribution of hairpin loops affected by twin mutations according to APOBEC 253 mutagenesis,

254 (E) DNA accessibility,

255 (F) number of mutations in TpC context within a loop and

256 (G) DNA sequence between twin mutations. Wilcoxon rank-sum test was applied to compare
 257 APOBEC *vs* non-APOBEC tumors and p-values were Benjamini-Hochberg corrected.

258 See also Figures S7-S9 and Tables S2 and S3.

259

260 Next, we investigated the properties and origin of these twin mutations. A comprehensive analysis of all DNA hairpin-loop structures in the human genome affected by two mutations in their loops revealed 261 262 2,387 twin mutations (4,774 altered genomic positions), representing 0.16% of all mutated genomic 263 positions. The distance between twin mutations varied, but when the frequency of mutations increased, 264 the distance decreased to mainly one or two bases and the loop sizes to mainly three to four bases 265 (Figure 4B). Additional examination of the 96 tri-nucleotide contexts of all twin mutations revealed that 266 both APOBEC COSMIC signatures, SBS2 and SBS13, were dominant (Figure 4C). However, at higher 267 mutational frequencies ($n \ge 5$), only signature SBS2 remained. We also observed a secondary signature 268 of C>T mutations in the ApC context that does not resemble any known COSMIC signature (Figure S8, 269 Table S2). The absolute contribution of this signature was similar across all APOBEC tumors and its 270 prevalence in the mUC cohort correlated with spontaneous deamination (SBS1) and defective DNA 271 mismatch repair signatures (Figure S9; SBS6, SBS15, SBS20 and SBS26).

Furthermore, APOBEC-driven tumors were enriched for twin mutations occurring only in the TpC context (Figure 4D). Contrary to the general pattern of ApoHM (enriched in DNA accessible regions), twin mutations with a high number of alterations were similarly distributed between high and low DNA accessible regions (Figure 4E).

Additionally, we found that at higher mutational frequency, at least one of the twin mutations occurs in the TpC context (**Figure 4F**) and the sequence between the two is 1001 or 101 (0 = A/T, 1 = G/C; underlined are the positions of the twin mutations) (**Figure 4G**). Because of the unique characteristics of frequently affected twin mutations, we named them didymi (twins in Greek). In summary, didymi are two C>T hotspot mutations found in DNA hairpin-loops separated by one or two A/T base-pairs in which at least one of the twin mutations is located in TpC context and the other in NpC (N = any base-pair;

282 most N bases are A or T). Applying this definition, we identified 231 didymi in the mUC cohort (**Table**283 **S3**).

284

285 Driver hotspot mutations in urothelial carcinoma

286 After identifying several hotspot mutations that could be attributed to APOBEC activity, we assessed 287 whether these hotspot mutations had a selective advantage (drivers) or not (passengers). Recent 288 attempts relying on the stability of hairpin-loops have been proposed to differentiate passengers from 289 driver ApoHM^{8,20}. We confirmed that a more stable loop (Gibbs free energy ΔG ; see STAR Methods) 290 leads to a higher number of alterations (Figure 5A). Taking this into account, we developed a statistical 291 model to identify driver hotspot mutations considering not only the stability of hairpin-loops but also the 292 tri-nucleotide context, DNA accessibility and the potential for didymi via sequence in the loop (Figure 293 5A).



295 Figure 5. Driver hotspot mutations associated with APOBEC mutagenesis in urothelial 296 carcinoma

- 297 (A) Frequency distribution of variables (trinucleotide context, DNA accessibility, DNA hairpin-loop 298 stability and sequence in the loop) considered to identify hotspot mutations that were more 299 frequently mutated than expected outside (top) and within (bottom) hairpin-loop structures.
- 300 (B) Driver hotpot mutations were estimated separately for mutations outside and within hairpin loops. Per group, p-values were corrected using the Benjamini-Hochberg method. 301
- 302 See also Figures S10 and S11, and Table S4.

303

Putative ApoHM were divided into those located outside or inside the loop of DNA hairpin-loop structures. In case of ApoHM outside hairpin-loops, only those in the TpC context were considered. For ApoHM within loops, all alterations in TpC, ApC, CpC and GpC context were included in the analysis to account for didymi. In case of TpC, the distribution of hotspot mutations in the trinucleotide context was considered. A background distribution was modeled as a Poisson process and the significant enrichment of mutations in a particular genomic site was estimated.

We identified 0.40% (n = 27) of ApoHM as drivers (adjusted p < 0.05; **Fig 5B**). Known driver genes affected by hotspot mutations included coding alterations in *TP53, PIK3CA, FGFR3, RXRA* and the *TERT* promoter. All other putative driver ApoHM affected non-coding regions including didymi in *ADGRG6, PLEKHS1, TBC1D12* and *LEPROTL1* proposed as drivers by other studies^{9,22}. Other potential driver ApoHM include *RNF169* (involved in DNA damage repair)²³, *BTG3* (angiogenesis)²⁴, *ADM* (adrenomedullin; vasodilator)²⁵, *GDF3* (regulation of TGF-beta)²⁶ and WDR74 (ribosome biogenesis)²⁷.

To validate our method and confirm the driver ApoHM assessment, we used an independent cohort of non-metastatic urothelial carcinoma of the bladder (n = 23) of the pan-cancer analysis of whole-genomes (PCAWG) study²⁸ (**Figure S10**). This analysis confirmed the previously identified ApoHM as potential cancer drivers of urothelial carcinoma. Moreover, in this cohort, 96% of tumors were APOBEC-driven, APOBEC enrichment correlated with kataegis and the largest group (35%) had high enrichment for APOBEC-associated mutations.

323 Furthermore, the performance of the model to identify driver ApoHM in hairpin loops was tested. The Q-324 Q plots show that the empirical distribution of ApoHM deviates from the theoretically expected distribution (Kolmogorov–Smirnov test p < 0.001). However, when outliers that represent highly frequent 325 326 ApoHM (>10) are excluded, which according to our analysis are all drivers, we observed a good 327 agreement between our model and the theoretical distribution (Figure S11A; Kolmogorov-Smirnov test 328 p = 0.19). By simulating a synthetic genome of mUC, we showed that an 80% statistical power is reached 329 when the cohort size is ~75 samples for highly frequent (>10%) driver ApoHM (Figure S11B). However, 330 the power to detect rare driver ApoHM ($\leq 10\%$) is considerably reduced, and a larger cohort is needed. 331 We also evaluated the contribution of different genomic features as covariates (Table S4) to identify

driver ApoHM. The McFadden's R^2 in the model that only considers the trinucleotide context is low (R^2 = 0.04), but the goodness of fit increases when considering the hairpin loop (R^2 = 0.23), hairpin-loop + sequence in the loop (R^2 = 0.27) and when adding DNA accessibility regions (R^2 = 0.28) into the model. DNA accessibility shows a high (anti-)correlation with other genomic features: GC content, RNA expression levels, mutational load, methylation and replication timing (**Figure S11C**). Therefore, the addition of the other variables in the model has limited added value (**Figure S11D**).

338

339 Driver hotspot mutations in metastatic breast cancer

- 340 To test our statistical framework in other cancer types and to evaluate if our findings were UC-specific,
- 341 we analyzed a cohort of 442 mBC (Figure 6)²⁹. Similar to UC, breast cancer is commonly affected by
- 342 APOBEC mutagenic activity¹. We identified APOBEC-enriched tumors in 76% of patients, and only 19%
- 343 of mBC tumors were APOBEC-high. In most patients (39%), tumors were classified as APOBEC-low
- and were enriched for HR deficiency (two-sided Fisher's exact p < 0.001).

medRxiv preprint doi: https://doi.org/10.1101/2023.08.09.23293865; this version posted February 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in





345



348 (A) Whole-genome sequencing data from 442 metastatic breast cancer were analyzed and patients were classified according to the enrichment of APOBEC-associated mutations. The genomic 349 350 features are displayed from top to bottom as follows: APOBEC mutagenesis; genome-wide tumor mutational burden (TMB); COSMIC mutational signatures; frequency of kataegis; 351 352 homologous recombination (HR) deficiency and its probable origin; cancer subtype and; the 353 most frequent hotspot mutations (known hotspot mutations in LEPROTL1, TBC1D12 and TERT 354 were also included).

(B) Putative driver hotspot mutations in APOBEC-enriched breast cancer. P-values were adjusted
 using the Benjamini-Hochberg method.

357 See also Figure S12 and Table S5.

358

The most frequent coding hotspot mutations affected *PIK3CA*, *ESR1* and *AKT1*. Twin mutations in hairpin-loops displayed a similar mutational signature as those in mUC, including the APOBEC signature SBS2 in conjunction with the uncharacterized C>T mutations in ApC context that define didymi (**Figure S12A-B**). Didymi in *PLEKHS1* and *ADGRG6* were the most frequent non-coding hotspot mutations, while *LEPROTL1* and *TBC1D12*, two other didymi frequently found in mUC, only affected ≤1% of mBC. A total of 694 didymi were identified in mBC (**Table S5**), but only 19 (2.7%) were shared with mUC (**Figure S12C**).

Our analysis revealed 51 driver ApoHM in APOBEC-enriched mBC (**Figure 6B**), representing only 0.07% of all ApoHM. Drivers included missense hotspot mutations in *PIK3CA*, *AKT1* and *TP53*, and hotspot mutations outside of the protein-coding region of *MAPKAPK2*, *STAG1* and including didymi in *PLEKHS1* and *ADGRG6*. In contrast to mUC, and despite being one of the most frequently affected genes by hotspot mutations in mUC, *LEPROTL1* was not a driver of mBC. This analysis suggests that driver mutations derived from APOBEC activity are cancer-type-specific.

372

373 Driver hotspot mutations across multiple metastatic cancers

APOBEC mutagenic activity is widespread across multiple cancer types. Here, we analyzed the genome of 16 additional metastatic cancers, which in total represents 3302 whole genomes (+115 mUC +442 mBC = 3859). Urothelial, breast and uterus cancers have the highest proportion of APOBEC-high tumors (**Figure 7A**). In mUC and mBC, 95% of hotspot mutations affect non-coding transcripts, introns or intergenic regions. This proportion varies per cancer type and can represent up to 99% of all hotspot mutations in esophagus cancer. Missense hotspot mutations are rare, but the highest proportion is found in liver cancer, reaching 5%.





382 Figure 7. Pan-cancer overview of APOBEC-derived hotspot mutations and drivers.

383 (A) Proportion of APOBEC-enriched tumors and hotspot mutations across cancer types.

- (B) Distribution of APOBEC-associated hotspot mutations (ApoHM) across the genome of
 APOBEC-enriched tumors.
- (C) The 10% most frequent genomic positions or genes affected by driver ApoHM. Drivers of
 specific cancer type are indicated by stars. The association of driver ApoHM with APOBEC fold
 enrichment (continuous values and using all tumor samples) using logistic regression analysis

and applying the Wald test (p adj < 0.05) shows the "true" APOBEC-derived mutations. All "true"
 APOBEC-derived driver ApoHM are included in the figure.

391 See also Tables S6 and S7.

392

The frequency of ApoHM increases with the strength of APOBEC mutagenesis and are more recurrent 393 394 in hairpin loops (Figure 7B). However, skin cancer does not follow this pattern, which has been proven 395 to be problematic in other studies due to its hypermutated nature, inflating the number of driver 396 events^{30,31}. These studies make special considerations or exclude skin cancer altogether from their 397 analysis. We found that skin cancer is mostly defined as an APOBEC-low cancer type and we suspected 398 that a large proportion of mutations that have the APOBEC signature may not have derived from 399 APOBEC mutagenic activity. This is supported by the relatively low number of driver ApoHM in skin 400 cancer that correlates with APOBEC enrichment (Figure 7C), despite many ApoHM defined as drivers 401 by our model (Table S6). These driver ApoHM considered "true" APOBEC-derived mutations are more 402 frequent in breast, urothelial, lung and uterus cancers. TERT, PIK3CA, PLEKHS1 and ADGRG6 are the 403 most affected genes by driver ApoHM. All four genes harbor two driver ApoHM, which are targeted by 404 APOBEC except for TERT that has only one "true" APOBEC-derived hotspot mutation (C250T). TP53 405 is another gene that is frequently affected by driver ApoHM, however, only one out of nine is a "true" 406 APOBEC-derived mutation. The pan-cancer overview exhibits the distribution of driver ApoHM in 407 APOBEC-enriched cancers, and the power gained by integrating 3859 samples revealed that of all 408 potential drivers, only 31 might be "true" APOBEC-derived mutations.

409

411 **DISCUSSION**

In this study, we describe the genomic landscape of APOBEC-driven tumors, characterize ApoHM and identify potential cancer drivers in mUC. The in-depth analysis of 115 whole-genomes of mUC identified chromatin accessibility, hairpin-loop stability and specific sequences within the hairpin-loop as variables associated with ApoHM. These variables, in combination with the mutational context, were used to identify ApoHM that were more frequently mutated than expected by chance.

417 The substrate of APOBEC enzymes is single-stranded DNA (ssDNA)¹, which has led to the following conflicting hypotheses: 1) APOBEC enzymes are mainly active during replication³² and 2) APOBEC is 418 419 mainly active in open chromatin and transcriptionally active genomic regions³³. The equal distribution of 420 all APOBEC-associated mutations across genomic regions supports the hypothesis that these 421 mutations had been generated during replication when APOBEC enzymes have equal access to ssDNA 422 across the genome³². However, kataegis which has previously been linked to APOBEC activity³⁴, and 423 ApoHM were enriched in high DNA accessible and highly transcribed regions. This observation 424 reconciliates both views claiming that APOBEC is active during DNA replication (non-clustered and non-425 hotspot mutations) and transcriptionally active regions (clustered and hotspot mutations). Additionally, 426 we observed that APOBEC3A-preferred YTCA mutations are dominant in mUC and are evenly 427 distributed across genomic regions. This result is in line with experimental observations in human cancer cell lines³⁴, suggesting that APOBEC3A is the main driver of APOBEC mutagenesis. For YTCA 428 429 mutations as well as for APOBEC3B-preferred RTCA mutations, the gap between the number of 430 mutations across genomic regions is smaller at higher APOBEC mutagenesis, which strongly suggests 431 that APOBEC enzymes do not have a preference for specific genomic regions. However, the enrichment 432 of highly frequent ApoHM ($n \ge 4$) in open chromatin, of which many are drivers according to our analysis, 433 may imply a functional effect of these putative driver mutations occurring near gene regulatory 434 elements²².

The extensive examination of ApoHM in hairpin-loops revealed twin mutations we termed didymi that are characterized by a unique mutational pattern. Didymi comprises the APOBEC SBS2 signature and an unknown signature delineated by C>T mutations in the ApC context. It is remarkable to see only one of the APOBEC signatures in didymi loci, when they usually appear together in tumor samples with APOBEC mutagenesis^{35,36}. The fact that only C>T mutations that characterize SBS2 are present in didymi suggests that these mutations may arise predominantly by replication across the uracil

bases^{37,38} and that the mechanisms to generate C>G mutations that characterize SBS13 are not
operational in this context. Furthermore, the unknown mutational signature of didymi correlates with
spontaneous deamination (SBS1) and defective DNA mismatch repair signatures (SBS6, SBS15,
SBS20 and SBS26), suggesting a potentially different mechanism in ApC from the putative TpC
APOBEC mutations. Although there is a strong correlation with APOBEC mutagenesis²¹, it is unclear if
both mutations in didymi loci are direct targets of APOBEC3A or whether the non-TpC mutations are
just the result of spontaneous deamination followed by DNA mismatch repair.

448 Compared to breast cancer, twice as many bladder cancer tumors were APOBEC-high (19% vs. 41%). 449 Most driver ApoHM were cancer-specific, possibly reflecting different selective pressures that each 450 cancer type endured. In both tumor types, APOBEC-low patients had enrichment for HR deficiency, 451 while APOBEC-high tumors had high tumor mutational burden which may indicate different treatment 452 options for these two groups of patients with different levels of APOBEC mutagenesis³⁹⁻⁴².

453 The in-depth analysis performed in this study to characterize the mutational landscape of APOBEC

454 mutagenesis, revealed the correlation of ApoHM with the stability of DNA hairpin-loops, DNA

455 accessibility and the potential for didymi associated with these recurrent mutations. These features are

456 key to modeling the background distribution of hotspot mutations and identifying potential drivers. Most

457 potential driver ApoHM were in the non-protein coding regions, including didymi. The similar frequency

458 of these drivers in the metastatic and primary settings of UC indicates a general phenomenon in UC

and the drivers could cause early events of tumorigenesis of UC. APOBEC-associated mutations have

460 also been identified in normal tissue^{43,44}, however, it is unclear if the driver ApoHM we report here are

461 also present in healthy tissue and to what extent they contribute to cancer development from normal

462 cells. Nevertheless, experimental validation will be needed to confirm the cancer driver status of these463 hotspot mutations.

Although several hotspot mutations are defined as drivers by our model, the inclusion of other cancer
types, increased the statistical power revealing that only 31 driver ApoHM have a strong correlation with
APOBEC, and may be considered "true" APOBEC-derived hotspot mutations.

In this study, we characterized the genomic landscape of APOBEC-driven mUC and identified novel
 mechanisms of genomic alteration patterns associated with APOBEC mutagenesis. The mutational
 signatures associated with DNA hairpin-loops targeted by APOBEC in two distinct hotspot positions are

470 unique, demonstrating the exclusive mutational signature of APOBEC-derived hotspot mutations. These 471 findings were confirmed in non-metastatic UC and in metastatic breast cancer. Additional studies are 472 needed to clarify the role of APOBEC in these recurrent twin mutations. Also, the enrichment of ApoHM 473 and kataegis in high DNA accessible regions, suggests a different mechanism compared to the general 474 APOBEC mutagenesis (non-hotspot mutations) that seems to occur independently of genomic regions, 475 which may be linked to different mechanisms of APOBEC3A and APOBEC3B¹³. As APOBEC is a major 476 source of hotspot mutations, it is crucial to identify those in coding and non-coding regions of whole-477 genomes that may play an important role in cancer development. The statistical framework we 478 developed could aid to identify potential driver hotspot mutations derived from APOBEC activity which 479 may offer novel targeted therapy options for APOBEC-driven cancer patients.

480

481 Limitations of the study

482 Despite the thorough analysis we have performed, caution should be exercised when considering these 483 outliers as true APOBEC-derived driver hotspot mutations as other unknown factors may still explain 484 the distribution of these highly frequent APOBEC-related hotspot mutations. The sample size for some 485 tumor types is a limitation when identifying driver hotspot mutations in a cancer-specific manner as we 486 did.

487 **ACKNOWLEDGEMENTS**

Hartwig Medical Foundation and the Center of Personalized Cancer Treatment are acknowledged for making the clinical, genomic and transcriptomic data available We would also like to thank the Pan-Cancer Analysis of Whole Genomes study for sharing the genomic data from 23 primary UC patients. We are particularly grateful to all participating patients and their families. The Stichting Dutch Uro-Oncology Study (DUOS) group and the Daniel den Hoed Foundation supported this research. J. Alberto Nakauma-González was collectively supported by the national funding organization the Dutch Cancer Society (KWF, the Netherlands) under the framework of the ERA-NET TRANSCAN-2 initiative.

495

496 AUTHORS CONTRIBUTIONS

Conceptualization: JAN and HJGvdW; Methodology: JAN and HJGvdW; Software: JAN, HJGvdW and
MTWN; Validation: JAN and HJGvdW; Formal Analysis: JAN and HJGvdW; Investigation: All authors;
Resources: JLB, JWMM; Data Curation: JAN, MR and HJGvdW; Writing – Original Draft: JAN and
HJGvdW; Writing – Review & Editing: All authors; Visualization: JAN; Supervision: JLB, HJGvdW, MPJL
and JWMM; Project Administration: JAN, HJGvdW, MPJL and JLB; Funding Acquisition: JLB , HJGvdW,
and MPJL.

503

504 DECLARATION OF INTERESTS

Joost L. Boormans has received research support from Merck AG / Pfizer, Janssen and Merck Sharp &
Dohme, and consultancy fees from Merck Sharp & Dohme, Bristol-Myers Squibb, Astellas, AstraZeneca,
Ipsen and Janssen (all paid to the Erasmus MC Cancer Institute).

508 Martijn P. J. Lolkema has received research support from JnJ, Sanofi, Astellas and MSD, and 509 consultancy fees from Incyte, Amgen, JnJ, Bayer, Servier, Roche, INCa, Pfizer, Sanofi, Astellas, 510 AstraZeneca, Merck Sharp & Dohme, Novartis, Julius Clinical and the Hartwig Medical Foundation (all 511 paid to the Erasmus MC Cancer Institute).

John W. M. Martens has received research support from Pfizer, Sanofi, GSK, Therawis Cergentis, and
Philips (all paid to the Erasmus MC Cancer Institute) and one consultancy fee from Novartis.

514 Astrid A.M. van der Veldt has received consultancy fees from BMS, MSD, Pfizer, Novartis, Eisai, Sanofi,

515 Pierre Fabre, Ipsen and Roche (all paid to the Erasmus MC Cancer Institute).

- 516 J. Alberto Nakauma-González, Maud Rijnders, Minouk T.W. Noordsij and Harmen J. G. van de Werken
- 517 declare no competing interests.

519 STAR METHODS

520

521 RESOURCE AVAILABILITY

- 522 Lead contact
- 523 Further information and requests for resources and reagents should be directed to and will be fulfilled
- 524 by the lead contact, Harmen J. G. van de Werken (h.vandewerken@erasmusmc.nl).

525 Materials availability

526 This study did not generate new unique reagents.

527 Data and code availability

528 WGS, RNA-seq and clinical data from mUC, mBC and from other metastatic cancers are available

- 529 through the Hartwig Medical Foundation at <u>https://www.hartwigmedicalfoundation.nl</u>, under request
- 530 numbers DR-314, DR-026 and DR-041 respectively. For mUC, samples that were previously analyzed
- 531 (DR-031) by Nakauma et al.¹⁰ were retrieved from DR-314. WGS data from primary UC was requested
- to the NCBI dbGAP and granted access through request #33427.
- 533 ChIPseq, replication timing and methylation data experiments, are freely available through The
- 534 ENCODE Project Consortium⁴⁶ and the Roadmap Epigenomics Consortium⁴⁷ on the ENCODE portal
- 535 (<u>https://www.encodeproject.org</u>)⁴⁵.
- 536 The scripts, including the algorithm to find hairpin-loops and estimate the thermodynamic stability have
- 537 been deposited in a public repository available at <u>https://github.com/ANakauma/ApobecHM_drivers</u>.
- 538 Additionally, the version v1.0.0 of the code used for this study (ApobecHM_drivers) is available at
- 539 Zenodo (https://doi.org/10.5281/zenodo.10362579)⁴⁸. Pre-processed WGS data was provided by the
- 540 Hartwig Medical Foundation and scripts are available at <u>https://github.com/hartwigmedical/hmftools.</u>
- 541 R2CPCT v0.4 was used for additional processing of the WGS (<u>https://github.com/J0bbie/R2CPCT</u>),

542

543

544 EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

545 Patient cohorts

- 546 The mUC cohort of this study has been previously described (NCT01855477 and NCT02925234)¹⁰. In
- short, patients with advanced or mUC were prospectively enrolled in these multicenter clinical trials and

548 were scheduled for 1st or 2nd line palliative systemic treatment. Following protocols of the Hartwig Medical Foundation (HMF)⁴⁹, WGS, with a depth close to 100X¹⁰, was successfully performed on DNA 549 550 from freshly obtained biopsies from metastatic sites, and matched RNA-sequencing (RNA-seq) was 551 available for 90 patients (97 samples). Sequential biopsies of a metastatic lesion taken at the time of 552 clinical or radiological disease progression from eight patients were additionally sequenced. Similarly, the cohorts of other cancer types have been previously described²⁹, and the DNA extraction and 553 sequencing were performed according to the HMF protocols⁴⁹. Only cancer types with >50 samples 554 555 were included in the analysis.

556

557 METHOD DETAILS

558 Whole-genome sequencing and analysis

Alignment and pre-processing of WGS data, detection of genomic subtypes, HR deficiency, MSI, 559 560 structural variants, chromothripsis events, APOBEC mutagenesis, and pathway activity have been previously described^{4,10,49,50}. Mutational signatures and kataegis were detected with MutationalPatterns 561 562 v3.10.0⁵¹ and Katdetectr v1.2.0⁵². APOBEC enriched tumors (adj. p < 0.01, otherwise non-APOBEC 563 tumors) were classified as high when the fold enrichment (E) for C>T and C>G mutations in TCW (W = A or T) context was $E \ge 3$, medium when $2 \le E < 3$ and low when E < 2. Similarly, the fold enrichment 564 for C>T and C>G mutations in the tetra YTCA (Y = T or C) and RTCA (R = G or A) context was 565 566 calculated.

567

568 **Clonal fraction and cancer cell fraction**

569 The clonal fraction of mutations was estimated as previously described⁵³. Correcting for tumor purity 570 and copy number, the variant copy number n_{SNV} of each SNV was calculated as follows

571
$$n_{SNV} = \frac{f_m}{p} [pC_t + (1-p)C_h], \qquad (1)$$

where f_m is the relative frequency of the mutant variant reads, p is the tumor purity, C_t is the copy number affecting the region where a particular SNV was located and C_h is the healthy copy number (2 for autosomes and 1 for allosomes). In this study, mutations were considered clonal when the variant copy number was >0.75.

To identify the proportion of cancer cells carrying a specific mutation, the cancer cell fraction (CCF) was estimated as previously described^{54,55}. Given the number of reference and mutant reads and assuming binomial distribution, we estimated the expected number of allelic copies (n_{chr}) carrying the observed SNV resulting from f_m values when the mutation is present in 1, 2, 3,..., N_{chr} allelic copies. The resulting estimated n_{chr} with the maximum likelihood is used to calculate the CCF as n_{SNV}/n_{chr} .

581

582 Mutational load across genomic regions

The genome was divided into regions (bins) of one mega base-pair (Mbp). The number of SNVs was counted in each bin, and the mean number of SNVs was estimated from the entire cohort. These values represented the average SNVs/Mbp reflecting the mutational load in each genomic region. The average SNVs/Mbp was smoothed by applying a moving average with a window of k = 3. For visualization reasons, in Figure 2 a k = 9 was used.

588

589 DNA accessibility estimation (ChIPseq)

590 ChIPseq data for healthy urinary bladder, breast and other tissues of adult humans (H3K4me1, 591 H3K4me3, H3K36me3 and H3K27ac) were downloaded from the ENCODE portal 592 (https://www.encodeproject.org) to our local server. The bed.gz files were imported with narrowPeak 593 format for analysis. Only peaks with q < 0.05 were kept for analysis. The signal of each experiment was 594 divided into regions of one Mbp, and a moving average with k = 3 bins was applied. The signals were 595 normalized using the mean and standard deviation. This procedure was applied to each chromosome. 596 The sum of all four ChIPseq experiments was considered an approximation of DNA accessibility. High 597 DNA accessible regions (open chromatin) had values above the median considering the whole genome. 598 All other regions were considered to be of low DNA accessibility (condensed chromatin). DNA 599 accessibility for all healthy tissues is available in Table S7 (for urinary bladder see Table S4 along with 600 other covariates). In case that matched normal ChIPseq with tumor type was not available, an average 601 of all ChIPseq experiments was used.

603 Detection of hairpin loops

All SNVs were assessed to determine whether they occur in the loop of hairpin-loop structures and their thermodynamic stability. A total of 50 bases upstream and downstream of the mutation site were considered. The minimum length of the stem was 2 base-pairs and the minimum and maximum loop size was 3 and 10 bases, respectively (not considering the closing base-pair). Since multiple configurations are possible, only the structure with the highest stability was considered. One mismatch was allowed which could be either a non-matching base-pair or a single nucleotide bulge loop.

610

611 Stability of hairpin loops

We implemented the nearest neighbor stability algorithm (NNSA) to estimate the thermodynamic stability of hairpin-loops. This algorithm calculates the Gibbs free energy (ΔG) of the DNA hairpin-loop structure based on known biophysics properties of the base pairs and their interactions^{56,57}.

The NNSA was applied to the target DNA sequence allowing mismatches in the stem. Each base-pair contributes to the stability of the stem considering the immediate neighboring base-pairs. Adding the local ΔG 's calculated per base and accounting for the size and sequence of the loop results in a final ΔG for the whole hairpin-loop structure. All parameters are available in the literature and the UNAFold web server was used to infer parameters for mismatches⁵⁶⁻⁵⁸. For loops larger than 4, no data was available for specific sequences and only the loop size was considered.

621

622 Driver hotspot mutations

To identify driver hotspot mutations, all genomic positions with 2 or more mutations were considered for analysis. Hotspot mutations were divided into two groups either located within loops of hairpin-loops or outside of these DNA structures. For hotspot mutations outside of loops, only those in the TpC context were considered, as these are likely initiated by APOBEC enzymes. For hotspot mutations falling within loops, all hotspot mutations in NpC (N = any base) context were considered, as APOBEC3A may also mutate these bases that are not in the TpC context²¹.

In cancer, only a few somatic mutations are drivers, while the vast majority are passenger mutations³⁰.
Under this consideration, we modeled the distribution of the remaining hotspot mutations as a Poisson
process per focal hotspot mutation. For more accurate modeling, we considered the tri-nucleotide

632 context TCW (TCA, TCC, TCG, TCT). In the case of hotspot mutations that do not occur in hairpin loops,
633 DNA accessibility was used as a predictor variable that can influence the distribution of hotspot
634 mutations. We modelled this in R as model_TCW_noloop=glm(n_mut_genpos+DNA_access). Where,
635 n_muts_genpos is a vector with the number of mutations per genomic position linked to the DNA
636 accessibility region (DNA_access). Accessibility regions were divided into 10 regions based on
637 percentiles. Since DNA-accessibility varies per tumor-tissue of origin^{59,60}, this was estimated for mUC,
638 mBC and other tumor types using ChIPseq experiments from normal tissue as described above.

- 639 In the case of hotspot mutations within hairpin-loops, the model was extended to include mutations in 640 non-TCW context (grouped as ApC, CpC or GpC context), the hairpin loop stability (hairpin stab) and 641 the DNA sequence in the loop (loopSeg): 642 model TCW loop=n mut genpos+DNA access+hairpin stab+loopSeg. The loop sequence was a binary variable to indicate whether the mutation occurred in the following sequence: 1001 or 101 (0 = 643 A/T, 1 = G/C; underlined is the position of the hotspot mutation). 644
- Using these models, we estimated the expected number of mutations of the specified hotspot mutation for which the model was built. Then, the exact Poisson test was applied to estimate the significance of observing the same or more mutations than expected in a specific genomic position. P-values were Benjamini-Hochberg adjusted. In rare occasions, only a few mutations (<2) were available to represent the background distribution of a particular tri-nucleotide. To include these ApoHM in the analysis, a model that did not consider the tri-nucleotide was used instead.

651

652 RNA-sequencing

Alignment, pre-processing of RNA-seq data and transcript normalization have been previously described^{10,29}. The transcriptomic subtype of each mUC sample was identified when the mean (normalized) expression of all genes associated with a specific subtype was the highest across all subtypes.

657

658 mRNA editing

Jalili, et al. identified hotspot mutations in the mRNA of *DDOST* that is targeted by APOBEC3A¹⁷. The genomic position of this hotspot mutation reveals a hairpin-loop structure that is an ideal substrate for

APOBEC3A. Due to the short life-time of mRNA molecules, the presence of this hotspot mutation reflects ongoing APOBEC mutagenesis. The proportion of C>U mutations in chr1:20981977 was estimated to identify the RNA-editing activity of APOEBC3A.

664

665 Transcriptome expression data mapped to genomic regions

666 MultiBamSummary from deepTools v1.30.0⁶¹ was used to read BAM files and estimate the number of 667 reads in genomic regions with a size of one Mbp. The average raw read count per Mbp was calculated, 668 and a moving average with k = 3 bins was applied. The scale of the read counts was normalized per 669 chromosome using the mean and standard deviation. High transcriptional regions were defined as such 670 when the expression value of one region was above the median of the whole genome.

671

672 Simulations and power calculation

673 A synthetic genome with 1.000,000 hotspot mutations was reconstructed from the original cohort of 674 mUC. To reach the number of hotspot mutations, non-hotspot mutations were randomly selected and 675 the number of mutations per genomic position was drawn from a Poisson distribution using the empirical 676 lambda from the mUC cohort. The same number of driver ApoHM identified in mUC were simulated as 677 hypothetical drivers to replicate a 3%-15% prevalence. Hypothetical cohorts with 10-500 samples were 678 simulated 100 times, using a random number of ApoHM derived from the empirical distribution of the 679 mUC cohort. The statistical power was estimated as the proportion of driver ApoHM that were correctly 680 identified. The performance of the model on simulated cohorts of 100 samples, was also tested with 681 other genomic covariates. These covariates were replication timing and methylation from HeLa cell lines, 682 and the proportion of GC content from the reference build hg19.

683

684 QUANTIFICATION AND STATISTICAL ANALYSIS

685 Statistical analysis

Analyses were performed using the statistical analysis platform R v4.1.0⁶². Fisher's exact, Wilcoxonrank sum and Wilcoxon signed-rank tests were used for comparison between groups. The correlation coefficients of continuous values with categorical values were estimated with logistic regression analysis applying the Wald test. Residuals for QQ plots and the Kolmogorov–Smirnov test were estimated using

- 690 DHARMa v.0.4.6⁶³. The exact Poisson test was applied to identify potential driver hotspot mutations.
- 691 The Poisson-binomial method was applied for mutually exclusive mutation events using Rediscover
- 692 v0.3.2⁶⁴ and the Fisher's exact test was applied for the significance of co-occurred mutations. In all
- 693 cases, p-values were adjusted using the Benjamini-Hochberg method.

694 SUPPLEMENTAL INFORMATION TITLES AND LEGENDS

- 695
- 696 Supplementary Figures. Figures S1-S12
- 697 Supplementary Tables. Tables S1-S7, Related to Figures 3-7

medRxiv preprint doi: https://doi.org/10.1101/2023.08.09.23293865; this version posted February 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

699 References

- 700 1. Roberts, S.A., Lawrence, M.S., Klimczak, L.J., Grimm, S.A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, 701 G.V., Carter, S.L., Saksena, G., et al. (2013). An APOBEC cytidine deaminase mutagenesis pattern is 702 widespread in human cancers. Nat. Genet. 45, 970-976. 10.1038/ng.2702.
- 703 Tate, J.G., Bamford, S., Jubb, H.C., Sondka, Z., Beare, D.M., Bindal, N., Boutselakis, H., Cole, C.G., 2. 704 Creatore, C., Dawson, E., et al. (2019). COSMIC: The Catalogue Of Somatic Mutations In Cancer. Nucleic. 705 Acids. Res. 47, D941-D947. 10.1093/nar/gky1015.
- 706 Boichard, A., Pham, T.V., Yeerna, H., Goodman, A., Tamayo, P., Lippman, S., Frampton, G.M., Tsigelny, 3. 707 I.F., and Kurzrock, R. (2019). APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications 708 for response to immunotherapy. Oncolmmunology 8, 1550341. 10.1080/2162402X.2018.1550341.
- 709 Rijnders, M., Nakauma-González, J.A., Robbrecht, D.G.J., Gil-Jimenez, A., Balcioglu, H.E., Oostvogels, 4. 710 A.A.M., Aarts, M.J.B., Boormans, J.L., Hamberg, P., van der Heijden, M.S., et al. (2024). Gene-expression-711 712 based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer. Nat. Commun. 15, 1349. 10.1038/s41467-024-45714-0.
- 713 714 715 716 5. Law, E.K., Levin-Klein, R., Jarvis, M.C., Kim, H., Argyris, P.P., Carpenter, M.A., Starrett, G.J., Temiz, N.A., Larson, L.K., Durfee, C., et al. (2020). APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. J. Exp. Med. 217. 10.1084/jem.20200261.
- 6. Sharma, S., and Baysal, B.E. (2017). Stem-loop structure preference for site-specific RNA editing by 717 APOBEC3A and APOBEC3G. PeerJ 5, e4136. 10.7717/peerj.4136.
- 718 7. Kumar, S., Warrell, J., Li, S., McGillivray, P.D., Meyerson, W., Salichos, L., Harmanci, A., Martinez-719 Fundichely, A., Chan, C.W.Y., Nielsen, M.M., et al. (2020). Passenger Mutations in More Than 2,500 720 Cancer Genomes: Overall Molecular Functional Impact and Consequences. Cell 180, 915-927.e916. https://doi.org/10.1016/i.cell.2020.01.032.
- 721 722 723 724 Shi, M.J., Meng, X.Y., Fontugne, J., Chen, C.L., Radvanyi, F., and Bernard-Pierrot, I. (2020). Identification 8. of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med. 12, 85-85. 10.1186/s13073-020-00781-y.
- 725 9. Wong, J.K.L., Aichmüller, C., Schulze, M., Hlevnjak, M., Elgaafary, S., Lichter, P., and Zapatka, M. (2022). 726 Association of mutation signature effectuating processes with mutation hotspots in driver genes and noncoding regions. Nat. Commun. 13, 178. 10.1038/s41467-021-27792-6.
- 727 728 729 730 10. Nakauma-González, J.A., Rijnders, M., van Riet, J., van der Heijden, M.S., Voortman, J., Cuppen, E., Mehra, N., van Wilpe, S., Oosting, S.F., Rijstenberg, L.L., et al. (2022). Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur. 731 Urol. 81, 331-336. https://doi.org/10.1016/j.eururo.2022.01.026.
- 732 Chan, K., Roberts, S.A., Klimczak, L.J., Sterling, J.F., Saini, N., Malc, E.P., Kim, J., Kwiatkowski, D.J., 11. 733 734 735 Fargo, D.C., Mieczkowski, P.A., et al. (2015). An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47, 1067-1072. 10.1038/ng.3378.
- 736 737 12. Roelofs, P.A., Timmermans, M.A.M., Stefanovska, B., den Boestert, M.A., van den Borne, A.W.M., Balcioglu, H.E., Trapman, A.M., Harris, R.S., Martens, J.W.M., and Span, P.N. (2023). Aberrant 738 APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase. Cells 12, 1185.
- 739 Hirabayashi, S., Shirakawa, K., Horisawa, Y., Matsumoto, T., Matsui, H., Yamazaki, H., Sarca, A.D., 13. 740 Kazuma, Y., Nomura, R., Konishi, Y., et al. (2021). APOBEC3B is preferentially expressed at the G2/M 741 phase of cell cycle. Biochem. Biophys. Res. Commun. 546. 178-184. 742 https://doi.org/10.1016/j.bbrc.2021.02.008.
- 743 Cortez, L.M., Brown, A.L., Dennis, M.A., Collins, C.D., Brown, A.J., Mitchell, D., Mertz, T.M., and Roberts, 14. 744 S.A. (2019). APOBEC3A is a prominent cytidine deaminase in breast cancer. PLoS Genet. 15, e1008545-745 e1008545. 10.1371/journal.pgen.1008545.
- 746 747 15. Glaser, A.P., Fantini, D., Wang, Y., Yu, Y., Rimar, K.J., Podojil, J.R., Miller, S.D., and Meeks, J.J. (2018). APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations 748 DNA damage response genes, and immune response. Oncotarget 9, 4537-4548. in 10.18632/oncotarget.23344.
- 749 750 Robertson, A.G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A.D., Hinoue, T., Laird, P.W., 16. 751 Hoadley, K.A., Akbani, R., et al. (2017). Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171, 540-556.e525. 10.1016/J.CELL.2017.09.007.
- 752 753 754 Jalili, P., Bowen, D., Langenbucher, A., Park, S., Aguirre, K., Corcoran, R.B., Fleischman, A.G., Lawrence, 17. M.S., Zou, L., and Buisson, R. (2020). Quantification of ongoing APOBEC3A activity in tumor cells by 755 monitoring RNA editing at hotspots. Nat. Commun. 11, 2971. 10.1038/s41467-020-16802-8.
- Allory, Y., Beukers, W., Sagrera, A., Flández, M., Marqués, M., Márquez, M., Van Der Keur, K.A., Dvrskiot, 756 18. 757 L., Lurkin, I., Vermeij, M., et al. (2014). Telomerase reverse transcriptase promoter mutations in bladder 758 cancer: High frequency across stages, detection in urine, and lack of association with outcome. Eur. Urol. 759 65, 360-366. 10.1016/j.eururo.2013.08.052.
- 760 Sirai, A.K., Bu, R., Igbal, K., Parvathareddy, S.K., Sirai, N., Sirai, S., Diaz, M.R.F., Rala, D.R., Benito, A.D., 19. 761 Sabido, M.A., et al. (2020). Telomerase reverse transcriptase promoter mutations in cancers derived from 762 organ sites among middle multiple eastern population. Genomics *112*, 1746-1753. 763 https://doi.org/10.1016/j.ygeno.2019.09.017

medRxiv preprint doi: https://doi.org/10.1101/2023.08.09.23293865; this version posted February 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- 764 20. Buisson, R., Langenbucher, A., Bowen, D., Kwan, E.E., Benes, C.H., Zou, L., and Lawrence, M.S. (2019). 765 Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science 766 364, eaaw2872-eaaw2872. 10.1126/science.aaw2872.
- 767 21. Langenbucher, A., Bowen, D., Sakhtemani, R., Bournique, E., Wise, J.F., Zou, L., Bhagwat, A.S., Buisson, 768 R., and Lawrence, M.S. (2021). An extended APOBEC3A mutation signature in cancer. Nat. Commun. 12, 769 1602. 10.1038/s41467-021-21891-0.
- 770 771 22. Wu, S., Ou, T., Xing, N., Lu, J., Wan, S., Wang, C., Zhang, X., Yang, F., Huang, Y., and Cai, Z. (2019). Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as 772 angiogenesis-related drivers in bladder cancer. Nat. Commun. 10, 1-12. 10.1038/s41467-019-08576-5.
- 773 An, L., Dong, C., Li, J., Chen, J., Yuan, J., Huang, J., Chan, K.M., Yu, C.-h., and Huen, M.S.Y. (2018). 23. 774 RNF169 limits 53BP1 deposition at DSBs to stimulate single-strand annealing repair. Proc. Natl. Acad. 775 Sci. U.S.A. 115, E8286-E8295. doi:10.1073/pnas.1804823115.
- 776 24. Cheng, Y.-C., Chiang, H.-Y., Cheng, S.-J., Chang, H.-W., Li, Y.-J., and Shieh, S.-Y. (2020). Loss of the 777 tumor suppressor BTG3 drives a pro-angiogenic tumor microenvironment through HIF-1 activation. Cell 778 Death Dis. 11, 1046. 10.1038/s41419-020-03248-5.
- 779 Fischer, J.-P., Els-Heindl, S., and Beck-Sickinger, A.G. (2020). Adrenomedullin - Current perspective on 25. 780 peptide hormone with significant therapeutic potential. Peptides 170347. 131, а https://doi.org/10.1016/j.peptides.2020.170347 781
- 782 Levine, A.J., and Brivanlou, A.H. (2006). GDF3 at the crossroads of TGF-beta signaling. Cell Cycle 5, 26. 783 1069-1073. 10.4161/cc.5.10.2771.
- 784 27. Lo, Y.-H., Romes, E.M., Pillon, M.C., Sobhany, M., and Stanley, R.E. (2017). Structural Analysis Reveals 785 Features of Ribosome Assembly Factor Nsa1/WDR74 Important for Localization and Interaction with 786 Rix7/NVL2. Structure 25, 762-772.e764. https://doi.org/10.1016/j.str.2017.03.008.
- Campbell, P.J., Getz, G., Korbel, J.O., Stuart, J.M., Jennings, J.L., Stein, L.D., Perry, M.D., Nahal-Bose, 787 28. 788 H.K., Ouellette, B.F.F., Li, C.H., et al. (2020). Pan-cancer analysis of whole genomes. Nature 578, 82-93. 789 10.1038/s41586-020-1969-6.
- 790 29. Angus, L., Smid, M., Wilting, S.M., van Riet, J., Van Hoeck, A., Nguyen, L., Nik-Zainal, S., Steenbruggen, 791 T.G., Tjan-Heijnen, V.C.G., Labots, M., et al. (2019). The genomic landscape of metastatic breast cancer 792 highlights changes in mutation and signature frequencies. Nat. Genet. 51, 1450-1458. 10.1038/s41588-793 019-0507-7.
- 794 30. Martincorena, I., Raine, K.M., Gerstung, M., Dawson, K.J., Haase, K., Van Loo, P., Davies, H., Stratton, 795 M.R., and Campbell, P.J. (2017). Universal Patterns of Selection in Cancer and Somatic Tissues. Cell 171, 796 1029-1041.e1021. 10.1016/j.cell.2017.09.042.
- 797 31. Juul, R.I., Nielsen, M.M., Juul, M., Feuerbach, L., and Pedersen, J.S. (2021). The landscape and driver 798 potential of site-specific hotspots across cancer genomes. NPJ Genom. Med. 6, 33. 10.1038/s41525-021-799 00197-6.
- 800 32. Hoopes, James I.I., Cortez, Luis M.M., Mertz, Tony M.M., Malc, Ewa P.P., Mieczkowski, Piotr A.A., and 801 Roberts, Steven A.A. (2016). APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand 802 Template during DNA Replication. Cell Rep. 14, 1273-1282.
- 803 Kazanov, M.D., Roberts, S.A., Polak, P., Stamatoyannopoulos, J., Klimczak, L.J., Gordenin, D.A., and 33. 804 Sunyaev, S.R. (2015). APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, 805 Gene-Dense, and Active Chromatin Regions. Cell Rep. 13, 1103-1109.
- 806 34. Petljak, M., Dananberg, A., Chu, K., Bergstrom, E.N., Striepen, J., von Morgen, P., Chen, Y., Shah, H., 807 Sale, J.E., Alexandrov, L.B., et al. (2022). Mechanisms of APOBEC3 mutagenesis in human cancer cells. 808 Nature 607, 799-807. 10.1038/s41586-022-04972-y.
- 809 Petljak, M., Alexandrov, L.B., Brammeld, J.S., Price, S., Wedge, D.C., Grossmann, S., Dawson, K.J., Ju, 35. 810 Y.S., Iorio, F., Tubio, J.M.C., et al. (2019). Characterizing Mutational Signatures in Human Cancer Cell 811 Lines Reveals Episodic APOBEC Mutagenesis. Cell 176, 1282-1294.e1220. 10.1016/j.cell.2019.02.012.
- 812 36. Alexandrov, L.B., Kim, J., Haradhvala, N.J., Huang, M.N., Tian Ng, A.W., Wu, Y., Boot, A., Covington, 813 K.R., Gordenin, D.A., Bergstrom, E.N., et al. (2020). The repertoire of mutational signatures in human 814 cancer. Nature 578, 94-101. 10.1038/s41586-020-1943-3.
- 815 Helleday, T., Eshtad, S., and Nik-Zainal, S. (2014). Mechanisms underlying mutational signatures in 37. 816 817 human cancers. Nat. Rev. Genet. 15, 585-598. 10.1038/nrg3729.
- 38. Petljak, M., and Maciejowski, J. (2020). Molecular origins of APOBEC-associated mutations in cancer. 818 DNA Repair 94, 102905. https://doi.org/10.1016/j.dnarep.2020.102905.
- 819 Patel, M., Nowsheen, S., Maraboyina, S., and Xia, F. (2020). The role of poly(ADP-ribose) polymerase 39. 820 inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell Biosci. 10, 35. 821 10.1186/s13578-020-00390-7.
- 822 Jekimovs, C., Bolderson, E., Suraweera, A., Adams, M., O'Byrne, K.J., and Richard, D.J. (2014). 40. 823 Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the 824 Bad, and the Promising. Front. Oncol. 4. 10.3389/fonc.2014.00086.
- 825 826 41. Gillyard, T., and Davis, J. (2021). Chapter Two - DNA double-strand break repair in cancer: A path to achieving precision medicine. In International Review of Cell and Molecular Biology, U. Weyemi, and L. 827 Galluzzi, eds. (Academic Press), pp. 111-137. https://doi.org/10.1016/bs.ircmb.2021.06.003.
- 828 42. Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H.C., Kindler, 829 H.L., Lopez-Martin, J.A., Miller, W.H., Jr., et al. (2020). Association of tumour mutational burden with 830 outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker

831		analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353-1365.
832		10.1016/s1470-2045(20)30445-9.
833	43.	Lawson, A.R.J., Abascal, F., Coorens, T.H.H., Hooks, Y., O'Neill, L., Latimer, C., Raine, K., Sanders, M.A.,
834		Warren, A.Y., Mahbubani, K.T.A., et al. (2020). Extensive heterogeneity in somatic mutation and selection
835		in the human bladder. Science 370, 75-82, 10,1126/science aba8347.
836	44	Wang Y Robinson P.S. Coorens T.H.H. Moore L. Lee-Six H. Noorani A. Sanders M.A. Jung H.
837		Katainen R. Heuschkel R. et al (2023) APOREC mitagenesis is a common process in normal human
001		amplification. Not Const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of a const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis is a common process in normal number of the const. 55: 246-254. AI OD20 Indugenesis Induces Induc
000	45	Sindi intestine. Nat. Genet. 55, 240-254. 10. 1050/541500-022-01290-5.
039	45.	Davis, C.A., Hilz, B.C., Sioan, C.A., Chan, E.T., Davidson, J.M., Gabdank, I., Hilton, J.A., Jain, K.,
840		Baymuradov, U.K., Narayanan, A.K., et al. (2018). The Encyclopedia of DNA elements (ENCODE): data
841		portal update. Nucleic. Acids. Res. 46, D794-D801. 10.1093/nar/gkx1081.
842	46.	Dunham, I., Kundaje, A., Aldred, S.F., Collins, P.J., Davis, C.A., Doyle, F., Epstein, C.B., Frietze, S.,
843		Harrow, J., Kaul, R., et al. (2012). An integrated encyclopedia of DNA elements in the human genome.
844		Nature 489, 57-74. 10.1038/nature11247.
845	47.	Roadmap Epigenomics, C., Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi,
846		A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015). Integrative analysis of 111 reference human
847		epigenomes Nature 518 317-329 10 1038/nature14248
848	48	Nakauma-González J.A. (2023) Whole-genome manning of APOBEC mutagenesis in metastatic
8 <u>4</u> 0	40.	urathalial carcinoma identifies driver hotspot mutations and a novel mutational signature. Zanodo
040		bitrouidei archio 5291/2009de 10262570
000	40	<u>Inites.//doi.org/10.3261/261000.10502573</u>
001	49.	Priestiey, P., Baber, J., Lokema, W.P., Steegns, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haldan, S.,
852		van Hoeck, A., Onstenk, W., et al. (2019). Pan-cancer whole-genome analyses of metastatic solid tumours.
853		Nature 575, 210-216. 10.1038/s41586-019-1689-y.
854	50.	van Dessel, L.F., van Riet, J., Smits, M., Zhu, Y., Hamberg, P., van der Heijden, M.S., Bergman, A.M., van
855		Oort, I.M., de Wit, R., Voest, E.E., et al. (2019). The genomic landscape of metastatic castration-resistant
856		prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat. Commun. 10, 1-13.
857		10.1038/s41467-019-13084-7.
858	51.	Blokziji, F., Janssen, R., van Boxtel, R., and Cuppen, E. (2018), MutationalPatterns; Comprehensive
859		genome-wide analysis of mutational processes. Genome Med 10, 33-33, 10, 1186/s13073-018-0539-0
860	52	Hazelaar DM van Riet I Hoostrate V and van de Werken H IG (2023) Katdetectr: an
861	02.	R/bioconductor package utilizing unsupervised changemont analysis for robust katagais detection
862		Cigoscionee 12 giod021 10 1002/gioscionee/giod021
002	E 2	Starbana D L. Tarnavi, D S. Davias H. Van Las D. Craanman C. Wadra D C. Nik Zainal S. Martin
003	55.	Stephens, P.J., Tarbey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge, D.C., Nik-Zama, S., Martin,
804		S., Vareia, I., Bigneli, G.R., et al. (2012). The landscape of cancer genes and mutational processes in
865		breast cancer. Nature 486, 400-404. 10.1038/nature11017.
866	54.	Bolli, N., Avet-Loiseau, H., Wedge, D.C., Van Loo, P., Alexandrov, L.B., Martincorena, I., Dawson, K.J.,
867		lorio, F., Nik-Zainal, S., Bignell, G.R., et al. (2014). Heterogeneity of genomic evolution and mutational
868		profiles in multiple myeloma. Nat. Commun. 5, 2997-2997. 10.1038/ncomms3997.
869	55.	Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L.B., Tubio, J.M.C., Papaemmanuil, E., Brewer, D.S.,
870		Kallio, H.M.L., Högnäs, G., Annala, M., et al. (2015). The evolutionary history of lethal metastatic prostate
871		cancer. Nature 520. 353-357. 10.1038/nature14347.
872	56.	Santal ucia, J. (1998). A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor
873		thermodynamics Proc Natl Acad Sci U.S.A. 95 1460-1465 doi:10.1073/ppas.954.1460
874	57	John Santal ucia I and Hicks D (2004) The Thermodynamics of DNA Structural Motifs Annu Rev
875	07.	Biophys Biophys Biophys 32 415-440 10 1146/appurey biophys 32 110601 141800
976	50	Biophys. Biomol. Studet. 30, 410-440. To: http://amilev.biophys.32. 10001. 14 1000.
070	50.	Zuker, IV. (2003). Milliou web server for indicate activitioning and hybridization prediction. Nucleic. Actus.
0//	50	Res. 37, 3400-3415. 10. 1093/nar/gkg595.
8/8	59.	Polak, P., Karlic, R., Koren, A., Thurman, R., Sandstrom, R., Lawrence, M.S., Reyholds, A., Rynes, E.,
879		Vlahoviček, K., Stamatoyannopoulos, J.A., and Sunyaev, S.R. (2015). Cell-of-origin chromatin
880		organization shapes the mutational landscape of cancer. Nature <i>518</i> , 360-364. 10.1038/nature14221.
881	60.	Kübler, K., Karlić, R., Haradhvala, N.J., Ha, K., Kim, J., Kuzman, M., Jiao, W., Gakkhar, S., Mouw, K.W.,
882		Braunstein, L.Z., et al. (2019). Tumor mutational landscape is a record of the pre-malignant state. bioRxiv,
883		517565. 10.1101/517565.
884	61.	Ramírez, F., Ryan, D.P., Grüning, B., Bhardwai, V., Kilpert, F., Richter, A.S., Heyne, S., Dündar, F., and
885		Manke, T. (2016), deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic.
886		Acids Res 44 W160-W165 10 1093/nar/gkw257
887	62	Team R.C. (2017) R Core Team (2017) R: A language and environment for statistical computing R
888	<u>.</u>	Foundation for Statistical Computing Vienna Austria LIRI http://www.R-project.org/ R Foundation for
880		Statistical Computing, R Foundation for Statistical Computing
800	63	Uartia E (2022) DUADMa: residual diagnostics for biorgraphical (multi-loval/mived) regression models
000 001	00.	haruy, T. (2022). DriAnvia. residual diagnosius for filerarchical (filuit-level/filixed) regression models.
091	C 4	nups.//iionannanig.gitnup.io/DHARMa/.
092	04.	rerrer-bonsoms, J.A., Jareno, L., and Rubio, A. (2021). Rediscover: an R package to identify mutually
893		exclusive mutations. Bioinformatics 38, 844-845. 10.1093/bioinformatics/btab709.
001		
094		